Searched for: in-biosketch:true
person:aa1565
High temporal resolution 3D gadolinium-enhanced dynamic MR imaging of renal tumors with pharmacokinetic modeling: Preliminary observations
Chandarana, Hersh; Amarosa, Alana; Huang, William C; Kang, Stella K; Taneja, Samir; Melamed, Jonathan; Kim, Sungheon
PURPOSE: To assess dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) tracer pharmacokinetic parameters obtained with Generalized Kinetic Model (GKM) and extended Shutter Speed Model (SSM2) in renal tumors stratified by histologic subtypes. MATERIALS AND METHODS: In all, 24 patients with renal tumors were imaged at 1.5 T utilizing DCE-MRI with high temporal resolution (1.2 sec/temporal frame) prior to surgery. Tracer kinetic analysis was performed for the entire tumor using individualized aortic input function. GKM and SSM2 were employed to generate transfer constant (K(trans) ), plasma volume, and interstitial volume. These parameters, and DeltaK(trans) (K(trans) SSM2 - K(trans) GKM) were compared between tumors stratified by histologic subtype. RESULTS: There were 25 renal tumors: 15 clear cell, 4 papillary, 3 chromophobe, and 3 oncocytoma/oncocytic subtype. K(trans) GKM was significantly higher in chromophobe compared to other subtypes (P < 0.01). Using K(trans) GKM > 1.0 min(-1) , chromophobe were diagnosed with 100% sensitivity and 90.9% specificity. K(trans) SSM2 was higher than K(trans) GKM for all renal tumors except for all chromophobe and two clear cell subtype. Using K(trans) GKM > 1.0 min(-1) and Delta K(trans) < 0, chromophobe could be discriminated from other lesions with 100% accuracy. CONCLUSION: K(trans) obtained with GKM and SSM2 analysis can potentially discriminate chromophobe from other renal lesions with high accuracy. J. Magn. Reson. Imaging 2013;. (c) 2013 Wiley Periodicals, Inc.
PMID: 23389833
ISSN: 1053-1807
CID: 240022
Effect of autoimmune thyroid disease in older euthyroid infertile woman during the first 35 days of an IVF cycle
Reh, Andrea; Chaudhry, Sonal; Mendelsohn, Felicia; Im, Shelly; Rolnitzky, Linda; Amarosa, Alana; Levitz, Mortimer; Srinivasa, Suman; Krey, Lewis; Berkeley, Alan S; Grifo, James A; Danoff, Ann
In this case-control study of euthyroid first-cycle IVF patients >/= 38 years old with singleton baby, miscarriage, biochemical pregnancy, and no pregnancy outcomes from 2005-2008, we assayed frozen serum for autoimmune thyroid disease (AITD) and thyroid function at cycle start, trigger, and 4 and 5 weeks' gestation. AITD prevalence in older infertile women was similar across clinical outcomes, and although AITD was associated with a higher baseline TSH, TSH remained within acceptable ranges, suggesting that T(4) supplementation may not affect maternal outcomes in older euthyroid AITD patients through 5 weeks gestation
PMCID:3059547
PMID: 21047632
ISSN: 1556-5653
CID: 138179
EFFECT OF AUTOIMMUNE THYROID DISEASE (AITD) IN OLDER, EUTHYROID INFERTILE WOMEN UNDERGOING IN VITRO FERTILIZATION (IVF) [Meeting Abstract]
Reh, A.; Im, S.; Amarosa, A.; Rolnitzky, L.; Grifo, J.; Danoff, A.
ISI:000281441000647
ISSN: 0015-0282
CID: 113773
Evaluating the necessity for universal screening of prospective oocyte donors using enhanced genetic and psychological testing
Reh, Andrea; Amarosa, Alana; Licciardi, Frederick; Krey, Lewis; Berkeley, Alan S; Kump, Lisa
BACKGROUND To minimize the potential for harmful inheritable conditions, donors are rigorously screened according to standard guidelines, yet such guidelines may not be sufficient to exclude egg donors with certain known inheritable conditions. We compared universal screening of oocyte donors with Tay-Sachs, Fragile X, karyotype and Minnesota Multiphasic Personality Inventory-2 (MMPI-2) versus standard American Society of Reproductive Medicine (ASRM) guidelines that do not include such testing. METHODS In this 12 year retrospective cohort study, results of enhanced universal screening of all anonymous oocyte donor candidates from 1997 to 2008 at a university hospital oocyte donation program were reviewed. Primary outcomes were the frequency of oocyte donor candidates excluded as a result of enhanced universal screening (Tay-Sachs, Fragile X, karyotypic analysis and MMPI-2) versus basic screening according to ASRM guidelines. RESULTS Of 1303 candidates who underwent on-site evaluation, 47% passed the screening process, 23% were lost to follow-up and 31% were excluded. Genetic and psychological factors accounted for the most common reasons for candidate exclusion. Enhanced genetic screening excluded an additional 25 candidates (19% of all genetic exclusions) and enhanced psychological screening excluded an additional 15 candidates (12% of all psychological exclusions). Altogether enhanced screening accounted for 40 candidates (10%) of the total pool of excluded candidates. CONCLUSIONS Although our study is limited by its retrospective nature and center-specific conclusions, we show that enhanced comprehensive screening can exclude a significant number of candidates from an oocyte donor program and should be encouraged to assure optimal short-term and long-term outcomes for pregnancies achieved through oocyte donation
PMID: 20659910
ISSN: 1460-2350
CID: 111821